- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- ASTRAZENECA PHARMA INDIA LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
ASTRAZENECA PHARMA Quarterly Results 
(AIDL)
Here are the latest quarterly results of ASTRAZENECA PHARMA. For more details, see the ASTRAZENECA PHARMA financial fact sheet and ASTRAZENECA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
ASTRAZENECA PHARMA Quarterly Results
| No. of Mths Qtr. Ending |
3
Sep-16 |
3
Dec-16 |
3
Mar-17* |
3
Jun-17 |
3
Sep-17 |
3
Dec-17 |
3
Mar-18 |
3
Jun-18 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 1,382 | 1,503 | 1,116 | 1,285 | 1,643 | 1,285 | 1,507 | 1,614 | |
| Other income | Rs m | 18 | 98 | 64 | 47 | 25 | 27 | 23 | 34 | |
| Turnover | Rs m | 1,400 | 1,601 | 1,180 | 1,331 | 1,668 | 1,312 | 1,531 | 1,649 | |
| Expenses | Rs m | 1,349 | 1,353 | 1,163 | 1,222 | 1,286 | 1,394 | 1,355 | 1,522 | |
| Gross profit | Rs m | 32 | 149 | -47 | 62 | 357 | -108 | 153 | 93 | |
| Depreciation | Rs m | 41 | 40 | 37 | 37 | 37 | 37 | 36 | 36 | |
| Interest | Rs m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Profit before tax | Rs m | 10 | 208 | -20 | 72 | 344 | -118 | 141 | 92 | |
| Tax | Rs m | 2 | 48 | 9 | 14 | 70 | -15 | 108 | 28 | |
| Profit after tax | Rs m | 8 | 160 | -29 | 58 | 274 | -104 | 32 | 64 | |
| Gross profit margin | % | 2.3 | 9.9 | -4.3 | 4.8 | 21.7 | -8.4 | 10.1 | 5.7 | |
| Effective tax rate | % | 19.4 | 23.1 | -44.4 | 19.1 | 20.4 | 12.4 | 77.1 | 30.1 | |
| Net profit margin | % | 0.6 | 10.6 | -2.6 | 4.5 | 16.7 | -8.1 | 2.1 | 4.0 | |
| Diluted EPS | Rs | 0.3 | 6.4 | -1.2 | 2.3 | 11.0 | -4.1 | 1.3 | 2.6 | |
| Diluted EPS (TTM) | Rs | 8.2 | 11.2 | 9.8 | 7.9 | 18.5 | 8.0 | 10.4 | 10.7 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: ASTRAZENECA PHARMA 1QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: CIPLA AUROBINDO PHARMA UNICHEM LAB FDC LTD. AMAR REMEDIES
Compare ASTRAZENECA PHARMA With: CIPLA AUROBINDO PHARMA UNICHEM LAB FDC LTD. AMAR REMEDIES
Compare ASTRAZENECA PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends Over 450 Points Lower; IT and Energy Stocks Witness Selling(Closing)
Share markets in India continued their sell-off seen during the day and ended the trading session deep in the red. All sectoral indices traded on a negative note with stocks in the IT sector.
Views on news
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)
Aug 21, 2018 | Updated on Aug 21, 2018For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 212.1% (Quarterly Result Update)
Jul 20, 2018 | Updated on Jul 20, 2018For the quarter ended March 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 32 m (down 212.1% YoY). Sales on the other hand came in at Rs 2 bn (up 35.1% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)
Oct 8, 2018While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.
My Top 3 Tips to Navigate the Market Crash(The 5 Minute Wrapup)
Oct 8, 2018Steep corrections are never easy to handle. It's hard to watch the value of your shares drop so much. But you can take steps to make the most of it.
IPO Market Feels the Heat of the Market Crash(Sector Info)
Oct 12, 2018The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.
Even If IL&FS Group Brought This Correction, this is Right Time to Buy & Sit Tight!(Chart Of The Day)
Oct 12, 2018Even if IL&FS is the culprit, it may turn out to be a hero if you buy right and sit tight.
ICICI Prudential Manufacture In India Fund: A Make In India Prodigy, Should You Invest?(Outside View)
Oct 8, 2018PersonalFN briefly explains if you should be investing in the NFO: ICICI Prudenetial Manufacture in India Fund.
More|
| |
ASTRAZENECA PHARMA SHARE PRICE
Oct 19, 2018 (Close)
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA - MYLAN COMPARISON
COMPARE ASTRAZENECA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.